2.63

7.72% -0.22

After Hours: 2.63

Pyxis Oncology Inc (PYXS)

Overview News Price History Option Chain Financials Why PYXS Down? Discussions Forecast

Pyxis Oncology Inc stock is traded at $2.63, with a volume of 692.71K. It is down -7.72% in the last 24 hours and up +53.80% over the past month. Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Previous Close:

$2.85

Open:

$2.79

24h Volume:

692.71K

Relative Volume:

0.95

Market Cap:

$166.62M

Revenue:

$13.86M

Net Income/Loss:

$-81.74M

P/E Ratio:

-2.0175

EPS:

-1.3036

Net Cash Flow:

$-66.98M

1W Performance:

+17.94%

1M Performance:

+53.80%

6M Performance:

+128.70%

1Y Performance:

+119.17%

1-Day Range:

$2.63

$3.00

1-Week Range:

$2.2019

$3.40

52-Week Range:

$0.97

$5.55

Pyxis Oncology Inc Stock (PYXS) Company Profile

Name

Pyxis Oncology Inc

Sector

Healthcare (1098)

Industry

Biotechnology (615)

Phone

(617) 221-9059

Address

321 HARRISON AVENUE, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

PYXS's Discussions on Twitter

Compare PYXS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PYXS Pyxis Oncology Inc	2.63	190.70M	13.86M	-81.74M	-66.98M	-1.3036
VRTX Vertex Pharmaceuticals Inc	528.04	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	654.27	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	939.68	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	312.78	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.24	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-03-25	Resumed	Stifel	Buy
Sep-04-25	Initiated	Guggenheim	Buy
Nov-21-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-08-24	Initiated	Stephens	Overweight
Aug-08-24	Initiated	Stifel	Buy
May-07-24	Resumed	Jefferies	Buy
Feb-09-24	Initiated	BTIG Research	Buy
Jan-23-24	Initiated	Leerink Partners	Outperform
Sep-05-23	Initiated	RBC Capital Mkts	Outperform
Nov-02-21	Initiated	BofA Securities	Neutral
Nov-02-21	Initiated	Credit Suisse	Outperform
Nov-02-21	Initiated	Jefferies	Buy

View All

Pyxis Oncology Inc Stock (PYXS) Latest News

05:57 AM

Leerink cuts Pyxis Oncology stock price target on valuation By Investing.com - Investing.com Canada

05:57 AM

Jul 01, 2026

Pyxis Oncology, Inc. Financial Disclosures & SEC Filings - TradingView

Jul 01, 2026

Pyxis Oncology Secures $114M for MICVO Cancer Trial - AllSci

Jul 01, 2026

Pyxis Oncology, Inc. Stock 12‑Month Price Target Raised to $7.14, Implies 137% Upside - TradingView

Jul 01, 2026

Latham & Watkins Advises on Pyxis Oncology’s Up to US$114 Million Private Placement Financing - Legal Desire Media and Insights

Jul 01, 2026

Jun 30, 2026

Latham Advises on Pyxis Oncology Up to Private Placement Financing - Latham & Watkins LLP

Jun 30, 2026

William Blair Maintains Pyxis Oncology(PYXS.US) With Hold Rating - Moomoo

Jun 30, 2026

[144] Pyxis Oncology, Inc. SEC Filing - Stock Titan

Jun 30, 2026